Key result
Proper management of hypertension and diabetes mellitus in patients with chronic kidney disease can slow disease progression and reduce healthcare expenditures.
Proper pharmacologic management of hypertension and diabetes in CKD patients, along with awareness of adverse events, can slow kidney disease progression and improve quality of life.
Hypertension and diabetes mellitus are the two leading causes of chronic kidney disease (CKD). The purpose of this paper is to provide an overview of the present pharmacologic and adverse events involved in the treatment of hypertension and diabetes mellitus in patients with CKD. Proper management of hypertension and diabetes mellitus, a common co-morbidity associated with CKD, would slow the progression of kidney disease and reduce healthcare expenditures. Awareness of potential side effects due to the medications or renal insufficiency could prevent unnecessary harm to the patient and provide cost-containment. Active involvement of all healthcare team members can reduce progression of CKD and improve quality of life outcomes in CKD patients.
No takes yet. Share an insight, caveat, or question.
Rasu et al. (2007) conducted a review in Chronic kidney disease with hypertension and diabetes mellitus. Pharmacologic treatment of hypertension and diabetes mellitus was evaluated. Proper management of hypertension and diabetes mellitus in patients with chronic kidney disease can slow disease progression and reduce healthcare expenditures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: